REFERENCES
1. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124:S4-13.
2. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276-83.
3. Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, et al. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. ASCRS. 2024.
4. Niu Y, Ji J, Yao K, Fu Q. Regenerative treatment of ophthalmic diseases with stem cells: principles, progress, and challenges. Adv Ophthalmol Pract Res. 2024;4:52-64.
5. Surico PL, Chen CB, Wang CW, et al. Umbilical cord-derived mesenchymal stem cell therapy for acute Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with severe ocular involvement. Ocul Surf. 2026;39:17-20.
6. Giebel B, Lim SK. Overcoming challenges in MSC-sEV therapeutics: insights and advances after a decade of research. Cytotherapy. 2025;27:843-8.
7. Liu X, Hu L, Liu F. Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases. Extracell Vesicles Circ Nucl Acids. 2022;3:102-17.
8. An W, Zhang W, Qi J, et al. Mesenchymal stem cells and mesenchymal stem cell-derived exosomes: a promising strategy for treating retinal degenerative diseases. Mol Med. 2025;31:75.
9. Chopra P, Fatima A, Mohapatra S, et al. Extracellular vesicles in dry eye disease and Sjögren’s syndrome: a systematic review on their diagnostic and therapeutic role. Surv Ophthalmol. 2025;70:499-515.
10. Chan SM, Tsai C, Lee TP, Huang ZR, Huang WH, Lin CT. Therapeutic potential of umbilical cord MSC-derived exosomes in a severe dry eye rat model: enhancing corneal protection and modulating inflammation. Biomedicines. 2025;13:1174.
11. Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmology. 2016;123:2300-8.
12. Caban M, Owczarek K, Lewandowska U. The role of metalloproteinases and their tissue inhibitors on ocular diseases: focusing on potential mechanisms. Int J Mol Sci. 2022;23:4256.
13. Hsiung CN, Lien WY, Sieber M, Lin WH. Omic profiling of extracellular vesicles from two cord-related sources reveals divergent effects on melanogenesis. Curr Issues Mol Biol. 2026;48:391.
14. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523-30.
15. Robciuc A, Arvola RPJ, Jauhiainen M, Holopainen JM. Matrix regeneration agents improve wound healing in non-stressed human corneal epithelial cells. Eye. 2018;32:813-9.
16. Way EE, Trevejo-Nunez G, Kane LP, et al. Dose-dependent suppression of cytokine production from T cells by a novel phosphoinositide 3-kinase delta inhibitor. Sci Rep. 2016;6:30384.
17. Borba PB, Torres CLM, da Costa MVM, et al. Immunomodulatory and regenerative effects of human umbilical cord MSC-EVs in Cutaneous Leishmaniasis. Stem Cell Res Ther. 2025;16:655.
18. Ma B, Zhou Y, Liu R, et al. Pigment epithelium-derived factor (PEDF) plays anti-inflammatory roles in the pathogenesis of dry eye disease. Ocul Surf. 2021;20:70-85.
19. Singh RB, Blanco T, Mittal SK, et al. Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease. Ocul Surf. 2020;18:460-9.
20. Singh RB, Blanco T, Mittal SK, et al. Pigment Epithelium-derived Factor enhances the suppressive phenotype of regulatory T cells in a murine model of dry eye disease. Am J Pathol. 2021;191:720-9.
21. Ho TC, Fan NW, Yeh SI, Chen SL, Tsao YP. The therapeutic effects of a PEDF-derived short peptide on murine experimental dry eye involves suppression of MMP-9 and inflammation. Transl Vis Sci Technol. 2022;11:12.
22. Sankaranarayanan J, Kim HK, Kang JY, Kuppa SS, Yang HY, Seon JK. Comparative efficacy of exosomes derived from different mesenchymal stem cell sources in osteoarthritis models: an in vitro and ex vivo analysis. Int J Mol Sci. 2025;26:5447.
23. Shin S, Lee J, Kwon Y, et al. Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton’s jelly. Int J Mol Sci. 2021;22:845.
24. Liu B, Qiao G, Cao W, et al. Proteomics analyses reveal functional differences between exosomes of mesenchymal stem cells derived from the umbilical cord and those derived from the adipose tissue. Cell J. 2021;23:75-84.
25. Chen L, Gu C, Yang Y, He T, Zhang Q. Exosomal miR-146a derived from human umbilical cord mesenchymal stem cells alleviates inflammation and apoptosis in dry eye disease by targeting SQSTM1. Exp Eye Res. 2025;258:110490.
26. Kim H, Zhao Q, Barreda H, et al. Identification of molecules responsible for therapeutic effects of extracellular vesicles produced from iPSC-derived MSCs on Sjo¨gren’s syndrome. Aging Dis. 2021;12:1409-22.
27. Zhou T, He C, Lai P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv. 2022;8:eabj9617.
28. Li N, Gao Z, Zhao L, et al. MSC-derived small extracellular vesicles attenuate autoimmune dacryoadenitis by promoting M2 macrophage polarization and inducing Tregs via miR-100-5p. Front Immunol. 2022;13:888949.
29. Wang L, Wang X, Chen Q, et al. MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF-κB pathway. Ocul Surf. 2023;28:131-40.
30. Qiu CY, Bi JX, Cui XY, et al. miR-6089 alleviates inflammation and cell apoptosis through modulating the TLR4 pathway in mite-sensitized allergic rhinitis. J Inflamm Res. 2025;18:3243-54.
31. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90-100.
32. Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al.; + TFOS collaborator group. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387-450.
33. Shoari A, Coban MA, Hockla A, et al. Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. J Biol Chem. 2025;301:110258.
34. Charzewski Ł, Krzyśko KA, Lesyng B. Structural characterisation of inhibitory and non-inhibitory MMP-9-TIMP-1 complexes and implications for regulatory mechanisms of MMP-9. Sci Rep. 2021;11:13376.
35. Sharma C, Dobson GP, Davenport LM, Morris JL, Letson HL. The role of matrix metalloproteinase-9 and its inhibitor TIMP-1 in burn injury: a systematic review. Int J Burns Trauma. 2021;11:275-88.
36. Hwang JR, Huh JH, Lee Y, Lee SI, Rho SB, Lee JH. Insulin-like growth factor-binding protein-5 (IGFBP-5) inhibits TNF-α-induced NF-κB activity by binding to TNFR1. Biochem Biophys Res Commun. 2011;405:545-51.
